Calithera Biosciences is a clinical-stage bio-pharmaceutical company focused on fighting cancer and other diseases. Co.'s primary product candidate, telaglenastat, is a selective glutaminase inhibitor that blocks glutamine consumption in tumor cells and demonstrates synergistic antitumor effects with multiple anticancer therapies in preclinical studies. Co.'s another product candidate, CB-280, is an oral inhibitor of arginase, an enzyme that depletes the amino acid arginine. It is being developed for the treatment of cystic fibrosis. An additional arginase inhibitor, INCB001158, was discovered by Co. and is being developed by Incyte Corporation for oncology and hematology indications. The CALA stock yearly return is shown above.
The yearly return on the CALA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2014 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CALA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|